CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (NVIV) today announced that the company’s investigational Neuro-Spinal Scaffold has received the 2015 Becker’s Healthcare Spine Device Award. It is one of 25 devices that received this distinction from Becker’s Healthcare. According to their article, “Both ‘tried-and-true’ devices as well as new promising innovations are featured in this year’s awards.” Award nominees are determined by the publication’s editorial staff, in this case Becker’s Spine Review, and are vetted by a panel of industry experts.
Mark Perrin, InVivo Chief Executive Officer and Chairman, said, “We are very pleased to be receiving this notable award, especially from a publication as well respected as Becker’s Spine Review. I’d like to extend my gratitude to Becker’s for the recognition and to all of the members of the InVivo team for making this possible.”
For the full story, please visit the Becker’s Healthcare site, here: http://www.beckersspine.com/lists/item/25625-25-spine-device-awards-2015.html
About the Neuro-Spinal Scaffold
Following an acute spinal cord injury, the biodegradable Neuro-Spinal Scaffold is surgically implanted at the epicenter of the wound and is designed to act as a physical substrate for nerve sprouting. Appositional healing to spare spinal cord tissue, decreased post-traumatic cyst formation, and decreased spinal cord tissue pressure have been demonstrated in preclinical models of spinal cord contusion injury. The Neuro-Spinal Scaffold, an investigational device, has received a Humanitarian Use Device (HUD) designation and is currently being studied in an Investigational Device Exemption (IDE) pilot study for the treatment of patients with complete (AIS A) traumatic acute spinal cord injury.
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital and who now is affiliated with Massachusetts General Hospital. In 2011 the company earned the David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. The publicly-traded company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.
